SG Americas Securities
CADX

SG Americas Securities’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

SG Americas Securities’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-11,554
Closed -$73K – 3378
2013
Q3 		$73K Buy
+11,554
New +$73.4K ﹤0.01% 2732

Other funds holding CADX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SG Americas Securities's CADX Position: Q4 2013 in Review

SG Americas Securities sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q4 2013, closing a stake of 11,554 shares — an estimated $73K sold.

SG Americas Securities first reported a position in CADX in Q3 2013 and held it in 1 quarter. The position peaked at $73K in Q3 2013. 100 funds tracked by Wall St. Rank hold CADX as of Q4 2013.

  • SG Americas Securities reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q4 2013 after selling out during the quarter.
  • SG Americas Securities sold 11,554 CADENCE PHARMACEUTICALS, INC COM STK shares in Q4 2013, an estimated $73K.
  • SG Americas Securities first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 1 quarter.
  • SG Americas Securities's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $73K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q4 2013.

Based on SG Americas Securities's 13F filing for Q4 2013, filed 12 Feb 2014.